Daclizumab to Prevent Rejection after Cardiac Transplantation

Abstract

Daclizumab was efficacious as prophylaxis against acute cellular rejection after cardiac transplantation. Because of the excess risk of death, concurrent or anticipated use of cytolytic therapy with daclizumab should be avoided.

Induction Therapy in Renal Transplant Recipients

“…Cytokine release is not typically associated with this agent (Hershberger et al, 2005;Nashan et al, 1999). Like other IL-2 receptor antagonists, the risk of PTLD is not significantly increased with use (Cherikh et al, 2003).…”

“…Like basiliximab, daclizumab has been shown to decrease the incidence of acute cellular rejection when administered as an induction agent (Hershberger et al, 2005;Nashan et al, 1999). Given the favorable side effect profile, it is tolerated well in recipients, irrespective of co-morbid conditions.…”

Immunosuppressive Therapy After Cardiac Transplantation

“…The triple-drug protocol, even if modified (many centres skipping corticosteroids after a certain time) is still used around the globe. Adding a forth drug to the regime has been reported but became not standard [19,89].…”

Modern Immunosuppression Regimens in Kidney Transplantation

“…Daclizumab has been shown to decrease the incidence of acute cellular rejection when administered as an induction agent [66,67]. Given the favorable side effect profile, it is well tolerated, irrespective of co-morbid conditions.…”

“…Cytokine release is not typically associated with this agent [66,67]. Like basiliximab, the risk of infectious complications or PTLD is not significantly increased with use [64].…”